Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**[18F]F-RESCA-RND20** is an investigational fluorine-18-labeled immunoPET radiotracer designed to bind **Nectin cell adhesion molecule 4** and enable noninvasive PET/CT visualization of Nectin-4 expression in tumors. It is being evaluated as a diagnostic imaging probe in the recruiting, phase-not-specified NCT06715839 study of patients with digestive system carcinomas; the study assesses tracer biodistribution, tumor uptake, and preliminary diagnostic performance after injection. It is a diagnostic radiopharmaceutical rather than a therapeutic radioligand. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06715839))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]F-RESCA-RND20.